Romina Fakhraei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Romina Fakhraei has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Deshayne B. Fell
University of Ottawa, Canada
3 shared publicationsAbdool Yasseen
University of Toronto, Canada
2 shared publicationsAllison McGeer
Mount Sinai Hospital, Canada
2 shared publicationsDarine El-Chaâr
University of Ottawa, Canada
2 shared publications- Elizabeth Kathleen Darling
McMaster Midwifery Research Centre, McMaster University, Hamilton, Canada
2 shared publications Jon Barrett
McMaster University, Canada
2 shared publications
Latest Publications
- Open Access
- 10 June 2026
- Published by Elsevier in Gastro Hep Advances
- Vol. 5 (9) , 101031
Progression of Metabolic Dysfunction–Associated Steatohepatitis in US Adults Using Linked Records and Claims
- 10 June 2026
- Published by Elsevier in Gastro Hep Advances
- Vol. 5 (9) , 101031
Open AccessProgression of Metabolic Dysfunction–Associated Steatohepatitis in US Adults Using Linked Records and Claims
- Open Access
- 2 July 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 48, 101170
Group B Streptococcus disease during infancy and risk of subsequent neurodevelopmental impairments in young children: a population-based cohort study in Ontario, Canada
- 2 July 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 48, 101170
Open AccessGroup B Streptococcus disease during infancy and risk of subsequent neurodevelopmental impairments in young children: a population-based cohort study in Ontario, Canada
- Open Access
- 24 October 2024
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 39, 100914
Burden of infant group B Streptococcus disease and impact of maternal screening and antibiotic prophylaxis in Ontario, Canada: a population-based cohort study
- 24 October 2024
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 39, 100914
Open AccessBurden of infant group B Streptococcus disease and impact of maternal screening and antibiotic prophylaxis in Ontario, Canada: a population-based cohort study
- Open Access
- 16 August 2021
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 36 (1) , 144-155
Examining the role of pre‐pregnancy weight and gestational weight gain in allergic disease development among offspring: A population‐based cohort study in Ontario, Canada
Background: Studies suggest maternal weight and weight gain during pregnancy may influence foetal immunological development. However, their role in the aetiology of allergic disease is unclear.Objectives: We sought to examine the impact of maternal pre‐pregnancy body mass index (BMI) and gestational weight gain (GWG) on the incidence of four common paediatric allergic diseases.Methods: We conducted a retrospective, population‐based cohort study of all singleton live births in Ontario, Canada between 2012 and 2014, using maternal‐newborn records from the provincial birth registry linked with health administrative databases. Neonates were followed up to 7 years for anaphylaxis, asthma, dermatitis and rhinitis, identified through validated algorithms based on healthcare encounters. We multiply imputed missing data and employed Cox proportional‐hazards models to calculate adjusted hazard ratios (aHR) with 95% confidence intervals (CI). To test the robustness of our findings, we also conducted several sensitivity analyses, including probabilistic bias analyses for exposure and outcome misclassification. All methods were prespecified in a published protocol.Results: Of the 248,017 infants followed, 52% were born to mothers with a pre‐pregnancy BMI in the normal range and only 19% were born to mothers with adequate weight gain during pregnancy. Incidence rates (per 100,000 person‐days) for anaphylaxis, asthma, dermatitis and rhinitis were 0.22, 6.80, 12.41 and 1.54, respectively. Compared with normal BMI, maternal obesity was associated with increased hazards of asthma in offspring (aHR 1.08, 95% CI 1.05, 1.11), but decreased hazards of anaphylaxis (aHR 0.83, 95% CI 0.69, 0.99) and dermatitis (aHR 0.97, 95% CI 0.94, 0.99). In contrast, maternal underweight was associated with increased hazards of dermatitis (aHR 1.06, 95% CI 1.02, 1.10). We found no associations between pre‐pregnancy BMI and rhinitis or GWG and any allergic outcome, and no evidence of effect measures modification by infant sex.Conclusions: These findings provide support for the involvement of maternal pre‐pregnancy BMI in paediatric allergic disease development.
- 16 August 2021
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 36 (1) , 144-155
Open AccessExamining the role of pre‐pregnancy weight and gestational weight gain in allergic disease development among offspring: A population‐based cohort study in Ontario, Canada
Background: Studies suggest maternal weight and weight gain during pregnancy may influence foetal immunological development. However, their role in the aetiology of allergic disease is unclear.Objectives: We sought to examine the impact of maternal pre‐pregnancy body mass index (BMI) and gestational weight gain (GWG) on the incidence of four common paediatric allergic diseases.Methods: We conducted a retrospective, population‐based cohort study of all singleton live births in Ontario, Canada between 2012 and 2014, using maternal‐newborn records from the provincial birth registry linked with health administrative databases. Neonates were followed up to 7 years for anaphylaxis, asthma, dermatitis and rhinitis, identified through validated algorithms based on healthcare encounters. We multiply imputed missing data and employed Cox proportional‐hazards models to calculate adjusted hazard ratios (aHR) with 95% confidence intervals (CI). To test the robustness of our findings, we also conducted several sensitivity analyses, including probabilistic bias analyses for exposure and outcome misclassification. All methods were prespecified in a published protocol.Results: Of the 248,017 infants followed, 52% were born to mothers with a pre‐pregnancy BMI in the normal range and only 19% were born to mothers with adequate weight gain during pregnancy. Incidence rates (per 100,000 person‐days) for anaphylaxis, asthma, dermatitis and rhinitis were 0.22, 6.80, 12.41 and 1.54, respectively. Compared with normal BMI, maternal obesity was associated with increased hazards of asthma in offspring (aHR 1.08, 95% CI 1.05, 1.11), but decreased hazards of anaphylaxis (aHR 0.83, 95% CI 0.69, 0.99) and dermatitis (aHR 0.97, 95% CI 0.94, 0.99). In contrast, maternal underweight was associated with increased hazards of dermatitis (aHR 1.06, 95% CI 1.02, 1.10). We found no associations between pre‐pregnancy BMI and rhinitis or GWG and any allergic outcome, and no evidence of effect measures modification by infant sex.Conclusions: These findings provide support for the involvement of maternal pre‐pregnancy BMI in paediatric allergic disease development.
- Open Access
- 14 January 2020
- Published by Wiley in Obesity Reviews
- Vol. 21 (3) , e12972
Guidelines for the management of pregnant women with obesity: A systematic review
Summary: Multiple clinical practice guidelines (CPGs) have been established for pregnant women with obesity. The quality and consistency of recommendations remain unknown. The objective of this study is to conduct a systematic review to synthesize and appraise evidence from CPGs, available worldwide, for pregnant women affected by obesity. An experienced information specialist performed a rigorous search of the literature, searching MEDLINE, Embase, grey literature, and guideline registries to locate CPGs that reported on pregnancy care relating to obesity. CPGs related to antenatal care of pregnant women with obesity (pre‐pregnancy body mass index [BMI] ≥ 30 kg/m2) in low‐risk (eg, care provider = family physician or midwife) or high‐risk settings (eg, obstetrician or maternal fetal medicine) were included. CPGs were appraised for quality with independent data collection by two raters. Information was categorized into five domains: preconception care. care during pregnancy, diet and exercise during pregnancy, care immediately before, during, and after delivery, and postpartum care. The literature search yielded 2614 unique citations. Following screening of abstracts and full texts, 32 CPGs were included, with quality ranging between 0 and 100 on the AGREE II tool. The strongest evidence related to nutritional advice, exercise, and pregnancy risk counselling. Guidance was limited for timing of screening tests, antenatal visits and delivery, ideal postpartum care, and management of adverse pregnancy outcomes. Most guidelines in this population are not evidence based. Research is needed to bridge knowledge gaps pertaining to fetal antenatal surveillance, management of adverse outcomes and postpartum care, and enhance consistency across CPGs.
- 14 January 2020
- Published by Wiley in Obesity Reviews
- Vol. 21 (3) , e12972
Open AccessGuidelines for the management of pregnant women with obesity: A systematic review
Summary: Multiple clinical practice guidelines (CPGs) have been established for pregnant women with obesity. The quality and consistency of recommendations remain unknown. The objective of this study is to conduct a systematic review to synthesize and appraise evidence from CPGs, available worldwide, for pregnant women affected by obesity. An experienced information specialist performed a rigorous search of the literature, searching MEDLINE, Embase, grey literature, and guideline registries to locate CPGs that reported on pregnancy care relating to obesity. CPGs related to antenatal care of pregnant women with obesity (pre‐pregnancy body mass index [BMI] ≥ 30 kg/m2) in low‐risk (eg, care provider = family physician or midwife) or high‐risk settings (eg, obstetrician or maternal fetal medicine) were included. CPGs were appraised for quality with independent data collection by two raters. Information was categorized into five domains: preconception care. care during pregnancy, diet and exercise during pregnancy, care immediately before, during, and after delivery, and postpartum care. The literature search yielded 2614 unique citations. Following screening of abstracts and full texts, 32 CPGs were included, with quality ranging between 0 and 100 on the AGREE II tool. The strongest evidence related to nutritional advice, exercise, and pregnancy risk counselling. Guidance was limited for timing of screening tests, antenatal visits and delivery, ideal postpartum care, and management of adverse pregnancy outcomes. Most guidelines in this population are not evidence based. Research is needed to bridge knowledge gaps pertaining to fetal antenatal surveillance, management of adverse outcomes and postpartum care, and enhance consistency across CPGs.